TMCnet News

NetNoggin® announces the release of NetNog: #genesis® Cystic Fibrosis research
[October 19, 2018]

NetNoggin® announces the release of NetNog: #genesis® Cystic Fibrosis research


FREDERICK, Md., Oct. 19, 2018 /PRNewswire/ -- NetNoggin®, a premier market research agency that specializes in pharmaceutical marketing, has announced the release of its newest research, NetNog: #genesis® Cystic Fibrosis. https://netnoggin.net/products

Inspired by the consumer. (PRNewsfoto/NetNoggin)

"We started with a rare condition because we truly care about the patient's story, and this story needs to be heard," said Megan Newcomer, Marketing Director at NetNoggin®. "We have the ability, with NetNog: #genesis®, to look at the disease market as a whole and really analyze how we can improve it, and ideally, improve the lives of patients and caregivers who struggle with this condition."

NetNog: #genesis® Cystic Fibrosis offers pharmaceutical companies an unprecedented advantage by starting their research with:

  • Secondary research for a baseline understanding of the market
  • Dashboard analytics for a basic overview of the social media marketspace
  • Insights into real world patient and caregiver lexicon, unet needs, treatment flow process, journey, and reported outcomes
  • A comparison of secondary research with patients' and caregivers' actual market/disease perspectives to identify gaps and leverage points
  • Guidance on how to use NetNog: #genesis® market research for the next steps in product development



"Understanding the patient and disease, agnostic of your brand, allows better differentiation in the market, longer customer lifetime value, improved strategy innovation, and ultimately a higher ROI," said Newcomer. "Therefore, we recommend starting research with NetNog: #genesis®."

NetNog: #genesis® is foundational research grounded in netnography and supported with secondary research to provide context to the disease-state. Cystic fibrosis is the first disease-focused research published in the NetNog: #genesis® pipeline, however, Alzheimer's disease (including MCI), along with other research will be coming to market soon.


Visit https://netnoggin.net/products to learn more about NetNog: #genesis® Cystic Fibrosis.

About NetNoggin®
NetNoggin®, a subsidiary of Conger Consulting, LLC, is a premier market research agency that specializes in pharmaceutical marketing. NetNoggin® has expertise in market research; commercial, market, and clinical development; and communications to provide reliable research, presentations, and workshops. NetNoggin® was established in 2011. The founder, Diana Conger, has been involved in bringing over 20 pharmaceutical products to market and has in-depth knowledge of over 30 disease-states.

NetNoggin® Media Relations
If you would like more information about this topic, please contact Megan Newcomer.
Phone: 443-605-4451
E-mail: [email protected]

 

Cision View original content to download multimedia:http://www.prnewswire.com/news-releases/netnoggin-announces-the-release-of-netnog-genesis-cystic-fibrosis-research-300734067.html

SOURCE NetNoggin


[ Back To TMCnet.com's Homepage ]